Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 471-482, September 2006

Idiopathic erythrocytosis and other non-clonal polycythemias

  • Guido Finazzi, MD

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.:+39 035 269 493; Fax: +39 035 266 147.

Division of Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy

Department of Hematology, Kelsey–Seybold Clinic, Houston, TX, USA

Division of Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy

Baylor College of Medicine, Houston, TX, USA; Department of Pathophysiology, Charles University in Prague, Czech Republic

Idiopathic erythrocytosis (IE) is characterized by an increase of red blood cell mass without an identified cause. Its diagnosis is based on the exclusion of polycythemia vera (PV), secondary acquired polycythemias and various congenital primary and secondary polycythemias. The frequency of IE has been estimated to be 1.1 per 1000 subjects, which is higher than that observed in PV. Heterogeneous mechanisms underlying IE have been suggested, including ‘early’ PV and unrecognized secondary or congenital polycythemia. However, the transition of a patient initially classified as IE into PV is a rare occurrence, when more sophisticated diagnostic techniques are employed. IE is a stable disease with a low thrombotic risk and a low, if any, tendency to spontaneous progression to acute leukemia or myelofibrosis. Phlebotomy in patients with IE is controversial. Myelosuppressive drugs should be avoided since their use is associated with evolution into acute leukemia in about 10% of patients.

Key words: idiopathic erythrocytosis, polycythemia vera, secondary polycythemia, phlebotomy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(05)00091-5

doi:10.1016/j.beha.2005.07.006

Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 471-482, September 2006